Evidence map›Paper›PMID 39976032›Full record

ReviewCurrent pharmaceutical biotechnology2025

Advances in Molecular Docking Techniques for Targeting Protein Misfolding in Neurodegenerative Diseases.

Kuldeep Singh, Jeetendra Kumar Gupta, Shiv Narayan, Ketki Rani, Divya Jain, Prateek Porwal, Mukesh Chandra Sharma, Shivendra Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kuldeep SinghDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0001-8772-8157
Jeetendra Kumar GuptaDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0002-5819-371X
Shiv NarayanDepartment of Pharmacology, Goel Institute of Pharmacy and Sciences, Lucknow, India.
Ketki RaniDepartment of Chemistry, SGT College of Pharmacy, SGT University, Gurugram, 122505, Haryana, India.
Divya JainDepartment of Microbiology, School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.ORCID 0000-0001-7220-5687
Prateek PorwalDepartment of Chemistry, FS College of Pharmacy and Research Center, FS College of Pharmacy and Research Centre, FS University, Shikohabad, Uttar Pradesh, India.
Mukesh Chandra SharmaSchool of Pharmacy, Devi Ahilya Vishwavidalaya, Indore, (M.P.), India.
Shivendra KumarDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0002-2287-6981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease, represent a significant global health challenge with limited therapeutic options. Protein misfolding and aggregation, a common pathological hallmark in these disorders, have emerged as promising targets for therapeutic intervention. Molecular docking techniques have played a pivotal role in the identification and design of small molecules that can modulate protein misfolding, offering new hope for effective treatments. This review provides an overview of recent advancements in molecular docking techniques for targeting protein misfolding in neurodegenerative diseases. We discuss the principles and methodologies behind molecular docking, including various scoring functions and algorithms employed for accurate ligand-protein interactions. Additionally, we explore the use of molecular dynamics simulations and machine learning approaches to enhance the precision of docking studies. Furthermore, we highlight case studies and success stories where molecular docking has contributed to the discovery of potential drug candidates for neurodegenerative diseases. These include compounds that inhibit amyloid-β aggregation in Alzheimer's disease, α-synuclein oligomerisation in Parkinson's disease, and mutant huntingtin aggregation in Huntington's disease. We also discuss the problems and restrictions of molecular docking related to neurodegenerative diseases, such as how to accurately show the flexibility of proteins and why docking results need to be confirmed by experiments. We also discuss the structural biology methods, such as cryo-electron microscopy and X-ray crystallography, and how these techniques might help in improving molecular docking studies.

Indexed as

Molecular Docking SimulationNeurodegenerative DiseasesProteostasis DeficienciesAnimalsHumansMolecular Dynamics SimulationProtein Foldingdrug designMolecular dockingneurodegenerative diseasesoptimisation.peptidesprotein misfoldingsmall moleculestherapeutic strategies

Identifiers

PMID39976032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.